Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.88, $0.02 better than the analyst estimate of $0.86. Revenue for the quarter came in at $821.5 million versus the consensus estimate of $831.98 million.

GUIDANCE:

Edwards Lifesciences sees Q4 2017 EPS of $0.84-$0.94, versus the consensus of $0.91. Edwards Lifesciences sees Q4 2017 revenue of $855-895 million, versus the consensus of $871.9 million.

Edwards Lifesciences sees FY2017 EPS of $3.65-$3.85, versus the consensus of $3.78. Edwards Lifesciences sees FY2017 revenue of $3.2-3.4 billion, versus the consensus of $3.39 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.